CoV-2 N (196 a.a.)
E.Coli.
Sterile Filtered clear solution.
CoV-2 Nucleocapsid protein is >95% pure as determined SDS-PAGE.
Description
The E.Coli derived recombinant protein contains the Coronavirus 2019 middle region a.a. from the Nucleocapsid protein and fused to GST-6xHis tag at N-terminal and having a Mw. Of 48.4 kDa.
Product Specs
The 2019 novel coronavirus (2019-nCoV), a human-infecting coronavirus causing viral pneumonia, was discovered in a Wuhan, China fish market in December 2019.
2019-nCoV shares 87% identity with the 2018 SARS-CoV-2 bat coronavirus found in Zhoushan, eastern China. Despite some genetic diversity, the similar receptor-binding domain (RBD) structure suggests that 2019-nCoV may also bind to the human ACE2 receptor (angiotensin-converting enzyme 2).
While bats are considered the likely reservoir of 2019-nCoV, researchers suspect an intermediate animal host, possibly from the seafood market. Analysis suggests that 2019-nCoV's spike glycoprotein is a recombinant of a bat coronavirus and another unknown coronavirus.
This E. coli-derived recombinant protein consists of the middle region (amino acids 196) of the Coronavirus 2019 Nucleocapsid protein. It is fused to a GST-6xHis tag at the N-terminus and has a molecular weight of 48.4 kDa.
The product is a clear, sterile-filtered solution.
The CoV-2 Nucleocapsid protein solution is provided in a buffer containing 50mM Tris-HCl (pH 8), 1M Urea, and 50% Glycerol.
The CoV-2 Nucleocapsid Protein is shipped with ice packs. Upon receiving, it should be stored at -20°C.
The CoV-2 Nucleocapsid protein has a purity greater than 95% as determined by SDS-PAGE analysis.
E.Coli.
NTA Sepharose-Affinity Purification.
Product Science Overview
The Coronavirus 2019 Nucleocapsid (N) protein is a crucial structural component of the SARS-CoV-2 virus, the causative agent of the COVID-19 pandemic. This protein plays a significant role in the viral life cycle, including RNA packaging and virion assembly . The recombinant form of this protein, consisting of 196 amino acids, is widely used in research and diagnostic applications.
The Nucleocapsid protein is one of the four main structural proteins of SARS-CoV-2, alongside the Spike (S), Membrane (M), and Envelope (E) proteins . It is responsible for binding to the viral RNA genome, forming a ribonucleoprotein complex that is essential for the stability and replication of the virus . The N protein also interacts with other viral and host cellular components to facilitate the assembly and release of new virions .
Recombinant Nucleocapsid proteins are produced using various expression systems, such as bacterial, yeast, or mammalian cells. These recombinant proteins are crucial for studying the structure and function of the N protein, as well as for developing diagnostic assays and vaccines . The recombinant form of the N protein, consisting of 196 amino acids, retains the essential functional domains required for RNA binding and oligomerization .
The recombinant Nucleocapsid protein is extensively used in research to understand the molecular mechanisms of SARS-CoV-2 infection and replication . It is also a key component in various diagnostic assays, including rapid antigen tests and enzyme-linked immunosorbent assays (ELISAs), which detect the presence of viral proteins in patient samples . Additionally, the N protein is a target for the development of therapeutic interventions and vaccines .
